| Literature DB >> 32893357 |
Roy Spijkerman1,2,3, Lillian Hesselink1,2, Carlo Bertinetto4, Coen Cwg Bongers5, Falco Hietbrink1, Nienke Vrisekoop2,3, Luke Ph Leenen1, Maria Te Hopman5, Jeroen J Jansen4, Leo Koenderman2,3.
Abstract
The amplitude of the innate immune response reflects the degree of physiological stress imposed by exercise load. An optimal balance of exercise intensity and duration is essential for a balanced immune system and reduces the risk of dysfunction of the immune system. Therefore, it is hypothesized that neutrophils, as key players in the innate immune system, can be used as biomarker in detecting overtraining. The aim was to monitor the state of the innate immune system by phenotyping neutrophils during consecutive bouts of prolonged exercise. Study subjects were recruited from a cohort of walkers participating in a walking event on 3 consecutive days. Participants with immune deficiencies were excluded. Questionnaires to determine the physiological status of the participants were completed. Analysis of neutrophil receptor expression was done by a point-of-care fully automated flow cytometer. A total of 45 participants were recruited, of whom 39 participants were included for data analysis. Study participants had a median age of 64 (58-70) years. The absolute numbers CD16dim /CD62Lbright and CD16bright /CD62Ldim neutrophils were increased after the first 2 days of exercise followed by an adaptation/normalization after the third day. Participants with activated neutrophils (high CD11b expression) had an impaired physical feeling indicated by the participant on a lower visual analog scale compared to participants who did not have activated neutrophils (P = 0.017, P = 0.022). Consecutive days of prolonged exercise results in an initial systemic innate immune response, followed by normalization/adaptation. Increased neutrophil activation was associated with impaired physical feeling measured by a validated VAS score indicated by the participant. Fully automated point-of-care flow cytometry analysis of neutrophil phenotypes in a field laboratory might be a useful tool to monitor relevant differences in the systemic innate immune response in response to exercise.Entities:
Keywords: innate immune system; neutrophil; prolonged walking; repetitive exercise
Year: 2020 PMID: 32893357 PMCID: PMC8048637 DOI: 10.1002/JLB.5A0820-436R
Source DB: PubMed Journal: J Leukoc Biol ISSN: 0741-5400 Impact factor: 4.962
FIGURE 1Design of the study. Baseline data were collected 1 or 2 days before the start of the event and each day of walking within 30 min after completion of the exercise
Demographics of the study group. Continuous data are shown as median (interquartile range) and dichotomous data are shown as absolute amount (percentage)
| ( | |
|---|---|
| Age (years) | 64 (58–70) |
| Male | 24 (61%)/15 (39%) |
| Height (m) | 1.77 (1.68–1.81) |
| Weight (kg) | 82 (71–92) |
| Body mass index (kg/m2) | 26 (24–30) |
| Waist circumference (cm) | 96 (88–104) |
| Resting systolic blood pressure (mm Hg) | 136 (130–149) |
| Resting diastolic blood pressure (mm Hg) | 83 (74–90) |
| Resting heart rate (bpm) | 69 (59–77) |
| Exercise intensity day 1 (%) | 65 (59–73) |
| Distance walked ( | |
|
30 km | 19 (49%) |
|
40 km | 19 (49%) |
|
50 km | 1 (2%) |
| Average speed (km/h) | |
| Day 1 | 4.4 (4.0–4.8) |
| Day 2 | 4.3 (3.8–5.0) |
| Day 3 | 4.6 (4.0–5.0) |
| Medical history ( | |
| Cerebrovascular accident | 7 (18%) |
| Asthma | 7 (18%) |
| Deep venous thrombosis | 6 (15%) |
| Psychiatric disorder | 5 (13%) |
| Diabetes | 5 (13%) |
| Atrial fibrillation | 5 (13%) |
| Myocardial infarction | 3 (8%) |
| Malignancy | 3 (8%) |
| Medication use ( | |
| Statin s | 25 (64%) |
| Anticoagulants | 12 (31%) |
| Ace‐2 inhibitors | 9 (23%) |
| Diuretics | 5 (13%) |
| Alfa blockers | 5 (13%) |
| Beta blockers | 5 (13%) |
| Proton pump inhibitors | 5 (13%) |
| Antihistamines | 2 (5%) |
| Other psychiatric drugs | 6 (15%) |
| Other cardiovascular drugs | 5 (13%) |
FIGURE 2The absolute count of total white blood cells (A), monocytes (B), and neutrophils (C) show a significant increase on day 1, followed by a decrease in the following days (. Eosinophils (D) show the opposite effect, a slight decrease on day 1 and after that a significant increase. The total white blood cell count was obtained from the cell counter in the automated flow cytometer. The percentage monocytes and granulocytes were gated base of forward versus side scatter. The percentage of neutrophils and eosinophils were determined by CD16+ and CD16‐ in the CD16 granulocyte histogram. Total white blood cells are shown as scatter plot with mean and sd, tested with ANOVA repeated‐measures with a Bonferroni post hoc multiple comparison correction. The rest of the data are presented as a scatter plot with median and interquartile range, tested with Friedman's test, with Dunn's post hoc multiple comparison correction. Reference values (grey area) show laboratory test reference ranges of the American board of internal medicine; ns, not significant; * P < 0.05; ** P < 0.005; *** P < 0.0005; **** P < 0.0001
FIGURE 3A significant increase in absolute count of CD16. The CD16bright/CD62Lbright neutrophils (C) increase on day 1, decrease on day 2 and increase again on day 3. The median fluorescent intensity of neutrophil activation markers CD35 (D), CD11b (E), and CD10 (F) show no significant differences between the days. Neutrophils were gated based on CD16+ in the granulocyte population determined by forward versus side scatter. The 3 different neutrophil phenotypes (A‐C) were gated based on CD16/CD62L neutrophil plot. The MFI of activation markers (D‐F) was determined in the neutrophil population. Data are presented as a scatter plot with median and IQR, tested with Friedman's test and Dunn's post hoc multiple comparison correction. Reference values (grey area) show the interquartile range of healthy controls non‐walkers during the same event; ns, not significant; MFI, median fluorescent intensity; AU, arbitrary units; * P < 0.05; ** P < 0.005; *** P < 0.0005; **** P < 0.0001
FIGURE 4Linear correlation between the median fluorescent intensity (MFI) of the neutrophil markers CD11b and CD10 was demonstrated over different days of prolonged, repeated walking. Data are presented as a scatter plot with a linear regression line. At baseline, both CD11b and CD10 expression was low (A). At day 1, an increase was seen in both CD11b and CD10 with a linear correlation (R 2 = 0.91; P < 0.0001; B). At days 2 and 3, both markers decreased but remain linear correlated (R 2 = 0.83 and R 2 = 0.87; P < 0.0001; C‐D). An exponential relationship between the MFI of CD62L and CD11b was found. Data are presented as a scatter plot with 1 phase decay exponential nonlinear regression. Day 0 showed one clear population of not activated participants with 4 activated outliers on the left (R 2 = 0.76; A). At day 1, all participants had a decreased CD62L MFI. Only beyond a certain CD62L MFI decrease, CD11b increased as well (R 2 = 0.53; B). At days 2 and 3, the variation in CD62L MFI remained, but the neutrophil activation maker CD11b decreased (C‐D). MFI, median fluorescent intensity; AU, arbitrary units
Differences are shown between participants developing an increased level of the neutrophil activation marker CD11b at day 1 and participants who remain below the interquartile range (IQR) of baseline MFI CD11b values
| Normal CD11b at day 1 ( | High CD11b at day 1 ( |
| |
|---|---|---|---|
| Age | 61 (56–69) | 66 (60–70) | 0.23 |
| Male n (%) / female n (%) | 12 (66%)/6 (33%) | 12 (57%)/9 (43%) | 0.54 |
| Height (meter) | 1.78 (1.70–1.81) | 1.75 (1.66–1.81) | 0.56 |
| Weight (kg) | 80 (70–87) | 81 (69–94) | 0.58 |
| Body mass index (kg/m2) | 25 (22–29) | 26 (24–30) | 0.34 |
| Waist circumference (cm) | 95 (88–101) | 97 (87–105) | 0.79 |
| Resting systolic blood pressure (mm Hg) | 137 (130–149) | 135 (126–152) | 0.81 |
| Resting diastolic blood pressure (mm Hg) | 85 (77–92) | 80 (73–87) | 0.15 |
| Resting heart rate (bpm) | 65 (58–73) | 71 (59–77) | 0.41 |
| Exercise intensity day 1 (%) | 61 (54–71) | 65 (59–76) | 0.25 |
| Distance 30 km (n, %) | 6 (33%) | 13 (62%) | 0.07 |
| Distance 40/50 km (n, %) | 12 (66%) | 8 (38%) |
|
| Walking speed day 1 (km/h) | 4.6 (4.3–5.2) | 4.1 (3.6–4.6) |
|
| Walking speed day 2 (km/h) | 4.7 (4.1–5.2) | 4.1 (3.4–4.5) |
|
| Walking speed day 3 (km/h) | 4.9 (4.6–5.4) | 4.2 (3.7–4.6) |
|
| VAS feeling day 0 | 9.5 (8.2–9.8) | 8.9 (8.1–9.5) | 0.24 |
| VAS feeling day 1 | 8.9 (7.2–9.5) | 7.8 (6.2–8.3) |
|
| VAS feeling day 2 | 8.7 (7.5–9.6) | 8.8 (6.6–9.0) | 0.13 |
| VAS feeling day 3 | 8.9 (8.3–9.3) | 8.0 (6.8–8.7) |
|
| VAS effort day 1 | 5.5 (3.1–7.3) | 5.4 (4.9–7.0) | 0.74 |
| VAS effort day 2 | 5.3 (2.4–6.9) | 5.6 (2.7–6.9) | 0.70 |
| VAS effort day 3 | 5.2 (3.2–7.0) | 5.4 (2.4–6.6) | 0.79 |
| VAS muscle pain day 0 | 0.2 (0.0–0.7) | 0.3 (0.0–3.4) | 0.44 |
| VAS muscle pain day 1 | 1.0 (0.5–3.9) | 2.3 (0.8–4.8) | 0.32 |
| VAS muscle pain day 2 | 2.1 (0.3–3.9) | 2.0 (0.7–4.9) | 0.47 |
| VAS muscle pain day 3 | 1.9 (0.7–4.1) | 1.2 (0.4–3.7) | 0.53 |
| Painkiller usage day 1 (n, %) | 2 (11%) | 6 (29%) | 0.17 |
| Painkiller usage day 2 (n, %) | 3 (16%) | 8 (38%) | 0.13 |
| Painkiller usage day 3 (n, %) | 5 (28%) | 9 (42%) | 0.26 |
Continuous data are shown as median (IQR), the significance is tested with the Mann‐Whitney U‐test. Dichotomous data are shown as an absolute amount (percentage), the significance is tested with the Pearson chi‐square test; MFI, median fluorescent intensity; *significant.